Revelation Biosciences, Inc. (REVB)

$0.5017

-0.02 (-3.44%)
Rating:
Recommendation:
-
Symbol REVB
Price $0.5017
Beta 0.000
Volume Avg. 5.17M
Market Cap 11.748M
Shares () -
52 Week Range 0.404-11.29
1y Target Est -
DCF Unlevered REVB DCF ->
DCF Levered REVB LDCF ->
ROE 441.71% Strong Buy
ROA -109.61% Strong Sell
Operating Margin -
Debt / Equity -8200.58% Strong Sell
P/E -
P/B -72.51 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest REVB news


Healthcare
Biotechnology
NASDAQ Capital Market

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.